Regeneron Pharmaceuticals (REGN) Inventory (2012 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Inventory of $3.1 billion for Q2 2026, down 3.78% year-over-year from $3.2 billion in Q2 2025, and down 0.62% quarter-over-quarter from $3.1 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Inventory (2012 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Inventory history runs 15 years deep, the most recent figure standing at $3.1 billion for Q2 2026.
- In Q2 2026, Inventory fell 3.78% year-over-year to $3.1 billion; the TTM figure through Jun 2026 stood at $3.1 billion (down 3.78% YoY), while the FY2025 annual figure was $3.2 billion, up 3.68% from the prior year.
- Inventory for Q2 2026 stood at $3.1 billion, down from $3.1 billion in the prior quarter.
- The five-year high for Inventory was $3.3 billion in Q3 2025, with the low at $2.0 billion in Q1 2022.
- The 5-year median for Inventory is $2.8 billion (2024), against an average of $2.8 billion.
- Peak annual rise in Inventory reached 23.09% in 2022, while the deepest fall reached 8.0% in 2022.
- Regeneron Pharmaceuticals' Inventory stood at $2.4 billion in 2022, then increased by 7.44% to $2.6 billion in 2023, then grew by 19.64% to $3.1 billion in 2024, then climbed by 3.68% to $3.2 billion in 2025, then slipped by 3.64% to $3.1 billion in 2026.
- Business Quant data shows REGN's Inventory at $3.1 billion in Q2 2026, $3.1 billion in Q1 2026, and $3.2 billion in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.08 Bn |
| Mar 31, 2026 | 3.10 Bn |
| Dec 31, 2025 | 3.20 Bn |
| Sep 30, 2025 | 3.25 Bn |
| Jun 30, 2025 | 3.21 Bn |
| Mar 31, 2025 | 3.19 Bn |
| Dec 31, 2024 | 3.09 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Jun 30, 2024 | 2.87 Bn |
| Mar 31, 2024 | 2.71 Bn |
| Dec 31, 2023 | 2.58 Bn |
| Sep 30, 2023 | 2.56 Bn |
| Jun 30, 2023 | 2.51 Bn |
| Mar 31, 2023 | 2.42 Bn |
| Dec 31, 2022 | 2.40 Bn |
| Sep 30, 2022 | 2.41 Bn |
| Jun 30, 2022 | 2.22 Bn |
| Mar 31, 2022 | 1.99 Bn |
| Dec 31, 2021 | 1.95 Bn |
| Sep 30, 2021 | 2.05 Bn |